Marco Luciani

Marco Luciani

Auto-generated profile, based on publicly available information

Marco Luciani

Department of Internal Medicine Cantonal Hospital of Baden Baden Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in JACC
Verified
Journal Article
Closed access
LTLuca Troncone
Luca Troncone
MLMarco Luciani
Marco Luciani
MCMatthew Coggins
Matthew Coggins
EWElissa H. Wilker
Elissa H. Wilker
CHCheng-Ying Ho
Cheng-Ying Ho
FMFederica del Monte
Federica del Monte

1 May 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MLMarco Luciani
Marco Luciani
MMMauro Montalbano
Mauro Montalbano
LTLuca Troncone
Luca Troncone
CBCamilla Bacchin
Camilla Bacchin
KUKeita Uchida
Keita Uchida
FMFederica Del Monte
Federica Del Monte
Amyloid plaques and neurofibrillary tangles, the molecular lesions that characterize Alzheimer’s disease (AD) and other forms of dementia, are emerging as determinants of proteinopathies ‘beyond the brain’. This study aims to establish tau’s putative pathophysiological mechanistic roles and potential future therapeutic targeting of tau in heart failure (HF). A mouse model of tauopathy and human myocardial and brain tissue from patients with HF, AD, and controls was employed in this study. Tau protein expression was examined together with its distribution, and in vitro tau-related pathophysiological mechanisms were identified using a variety of biochemical, imaging, and functional approaches. A novel tau-targeting immunotherapy was tested to explore tau-targeted therapeutic potential in HF. Tau is expressed in normal and diseased human hearts, in contradistinction to the current oft-cited observation that tau is expressed specifically in the brain. Notably, the main cardiac isoform is high-molecular-weight (HMW) tau (also known as big tau), and hyperphosphorylated tau segregates in aggregates in HF and AD hearts. As previously described for amyloid-beta, the tauopathy phenotype in human myocardium is of diastolic dysfunction. Perturbation in the tubulin code, specifically a loss of tyrosinated microtubules, emerged as a potential mechanism of myocardial tauopathy. Monoclonal anti-tau antibody therapy improved myocardial function and clearance of toxic aggregates in mice, supporting tau as a potential target for novel HF immunotherapy. The study presents new mechanistic evidence and potential treatment for the brain–heart tauopathy axis in myocardial and brain degenerative diseases and ageing. Tangle-like aggregates of hyperphosphorylated tau are present in the heart of patients with dilated cardiomyopathy or Alzheimer’s disease. A mouse model of tauopathy recapitulates the pathological findings of the human disease. Disruption of microtubule de/tyrosination causes myocardial diastolic dysfunction observed in the mouse model, and it can be targeted with immunotherapy. Abbreviations: iDCM, idiopathic dilated cardiomyopathy; PAO, pre-amyloid oligomers; TOMA, tau oligomer monoclonal antibody.

1 June 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
NLNicola Luciani
Nicola Luciani
EMEugenio Mossuto
Eugenio Mossuto
DRDavide Ricci
Davide Ricci
MLMarco Luciani
Marco Luciani
MRMarco Russo
Marco Russo
MTMario Tumbarello
Mario Tumbarello
Prosthetic valve endocarditis (PVE) is an uncommon yet dreadful complication in patients with prosthetic valves that requires a distinct analysis from native valve endocarditis. The present study aims to investigate independent risk factors for early surgical outcomes in patients with PVE. A retrospective cohort study was conducted in 8 Italian Cardiac Surgery Units from January 2000 to December 2013 by enrolling all PVE patients undergoing surgical treatment. A total of 209 consecutive patients were included in the study. During the study period, the global rate of surgical procedures for PVE among all operations for isolated or associated valvular disease was 0.45%. Despite its rarity this percentage increased significantly during the second time frame (2007–2013) in comparison with the previous one (2000–2006): 0.58% vs 0.31% (P < 0.001). Intraoperative and in-hospital mortality rates were 4.3% and 21.5%, respectively. Logistic regression analysis identified the following factors associated with in-hospital mortality: female gender [odds ratio (OR) = 4.62; P < 0.001], shock status (OR = 3.29; P = 0.02), previous surgical procedures within 3 months from the treatment (OR = 3.57; P = 0.009), multivalvular involvement (OR = 8.04; P = 0.003), abscess (OR = 2.48; P = 0.03) and urgent surgery (OR = 6.63; P < 0.001). Despite its rarity, PVE showed a significant increase over time. Up to now, in-hospital mortality after surgical treatment still remains high (>20%). Critical clinical presentation and extension of anatomical lesions are strong preoperative predictors for poor early outcome.

23 February 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MMMarianna Meo
Marianna Meo
OMOlivier Meste
Olivier Meste
SSSergio Signore
Sergio Signore
ASAndrea Sorrentino
Andrea Sorrentino
ACAntonio Cannata
Antonio Cannata
MRMarcello Rota
Marcello Rota
Background: Diabetes is associated with prolongation of the QT interval of the electrocardiogram and enhanced dispersion of ventricular repolarization, factors that, together with atherosclerosis and myocardial ischemia, may promote the occurrence of electrical disorders. Thus, we tested the possibility that alterations in transmembrane ionic currents reduce the repolarization reserve of myocytes, leading to action potential ( AP ) prolongation and enhanced beat‐to‐beat variability of repolarization. Methods and Results: Diabetes was induced in mice with streptozotocin ( STZ ), and effects of hyperglycemia on electrical properties of whole heart and myocytes were studied with respect to an untreated control group (Ctrl) using electrocardiographic recordings in vivo, ex vivo perfused hearts, and single‐cell patch‐clamp analysis. Additionally, a newly developed algorithm was introduced to obtain detailed information of the impact of high glucose on AP profile. Compared to Ctrl, hyperglycemia in STZ ‐treated animals was coupled with prolongation of the QT interval, enhanced temporal dispersion of electrical recovery, and susceptibility to ventricular arrhythmias, defects observed, in part, in the Akita mutant mouse model of type I diabetes. AP was prolonged and beat‐to‐beat variability of repolarization was enhanced in diabetic myocytes, with respect to Ctrl cells. Density of Kv K + and L‐type Ca 2+ currents were decreased in STZ myocytes, in comparison to cells from normoglycemic mice. Pharmacological reduction of Kv currents in Ctrl cells lengthened AP duration and increased temporal dispersion of repolarization, reiterating features identified in diabetic myocytes. Conclusions: Reductions in the repolarizing K + currents may contribute to electrical disturbances of the diabetic heart.

12 May 2015 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
NLNicola Luciani
Nicola Luciani
RGRaphael De Geest
Raphael De Geest
GLGiuseppe Lauria
Giuseppe Lauria
PFPiero Farina
Piero Farina
MLMarco Luciani
Marco Luciani
MMMassimo Massetti
Massimo Massetti
After repair of acute type A aortic dissection, aortic complications can develop, and reoperations might be necessary. In our retrospective study, we wanted to assess early and late outcomes in this cohort of patients. From September 2005 to July 2012, 21 consecutive patients previously operated on for acute type A aortic dissection underwent 27 redo aortic surgical procedures. Indications for redo procedures were: enlargement of the false lumen in the residual aorta (18 events), severe aortic regurgitation with or without aortic root dilatation (8 events), suture dehiscence and pseudoaneurysm at the proximal or distal aortic graft anastomosis (5 events) or at the coronary button anastomosis in patients who previously underwent a Bentall procedure (1 patient). In all cases, total or partial cardiopulmonary bypass was used. Hypothermic cardiocirculatory arrest was needed in 22 (81%) procedures. Hospital mortality was 3.7% (1/27), reexploration for bleeding and paraplegia rates were 7.4% and 7.4%, respectively. Marfan patients received 3.2 procedures per patient vs. 1.5 in non-Marfan patients (p < 0.01). At a mean follow-up of 6.5 years, 2 aortic events occurred: 1 aortic death, and 1 additional aortic redo surgery. When procedures are carried out on elective basis, redo aortic surgery can be performed in all segments of the aorta with good early and late outcomes. Close lifelong clinical and radiological follow-up is mandatory. After repair of acute type A aortic dissection, Marfan patients are more prone to develop late complications, with a more rapid evolution.

1 February 2021 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TDThamonwan Diteepeng
Thamonwan Diteepeng
FMFederica del Monte
Federica del Monte
MLMarco Luciani
Marco Luciani
Background: In the last decades, cardiovascular diseases (CVD) have remained the first leading cause of mortality and morbidity in the world. Although several therapeutic approaches have been introduced in the past, the development of novel treatments remains an important research goal, which is hampered by the lack of understanding of key mechanisms and targets. Emerging evidences in recent years indicate the involvement of misfolded proteins aggregation and the derailment of protein quality control in the pathogenesis of cardiovascular diseases. Several potential interventions targeting protein quality control have been translated from the bench to the bedside to effectively employ the misfolded proteins as promising therapeutic targets for cardiac diseases, but with trivial results. Design: In this review, we describe the recent progresses in preclinical and clinical studies of protein misfolding and compromised protein quality control by selecting and reporting studies focusing on cardiovascular diseases including cardiomyopathies, cardiac amyloidosis, atherosclerosis, atrial fibrillation and thrombosis. Results: In preclinical models, modulators of several molecular targets (eg heat shock proteins, unfolded protein response, ubiquitin protein system, autophagy and histone deacetylases) have been tested in various conditions with promising results although lacking an adequate transition towards clinical setting. Conclusions: At present, no therapeutic strategies have been reported to attenuate proteotoxicity in patients with CVD due to a lack of specific biomarkers for pinpointing upstream events in protein folding defects at a subclinical stage of the diseases requiring an intensive collaboration between basic scientists and clinicians.